Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 10/20 | 1.00 |
| ▸ | FLT1 | P17948 | 10/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 9/20 | 1.00 |
| ▸ | FLT4 | P35916 | 4/20 | 1.00 |
| ▸ | CSF1R | P07333 | 3/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 8/20 | 0.72 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.70 |
| ▸ | AURKA | O14965 | 3/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.70 |
| ▸ | PLK4 | O00444 | 3/20 | 0.69 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw770249X SCHEMBL30957039 | 1.00 | TEK (1.00) | TEKFLT1RIPK1FLT4CSF1R | |
| Gw770249X SCHEMBL29638046 | 1.00 | TEK (1.00) | TEKFLT1RIPK1FLT4CSF1R | |
| SCHEMBL25008891 | 0.93 | FLT1 (0.87) | TEKFLT1RIPK1FLT4CSF1R | |
| SCHEMBL21085189 | 0.89 | TEK (0.80) | TEKFLT1RIPK1FLT4CSF1R | |
| SCHEMBL3524617 | 0.85 | TEK (0.75) | TEKFLT1RIPK1FLT4CSF1R | |
| SCHEMBL3113394 | 0.84 | KDR (1.00) | TEKFLT1RIPK1FLT4CSF1R | |
| SCHEMBL22374875 | 0.83 | TEK (0.71) | TEKFLT1RIPK1FLT4CSF1R | |
| SCHEMBL24710786 | 0.83 | FLT1 (0.71) | TEKFLT1RIPK1FLT4CSF1R | |
| SCHEMBL13708284 | 0.83 | KDR (0.80) | TEKFLT1RIPK1FLT4CSF1R | |
| SCHEMBL14014000 | 0.82 | AURKA (0.81) | TEKFLT1RIPK1FLT4CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | claimed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | claimed |
| EP-3731841-A1 | COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF | Evergreen Biosciences (US) | 2020-11-04 | — | — | EP | claimed |
| CN-111655258-A | Compositions for cryopreservation and methods of use thereof | 常青树生物科学公司 | 2020-09-11 | — | — | CN | claimed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | claimed |
| US-20190201381-A1 | COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF | EVERGREEN BIOSCIENCES (US) | 2019-07-04 | — | — | US | claimed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | claimed |
| US-12053454-B2 | Compositions for cryopreservation and methods of use thereof | EVERGREEN BIOSCIENCES (US) | 2024-08-06 | — | — | US | disclosed |
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-117320754-A | Prostatitis treatment | 北京生命科学研究所 | 2023-12-29 | — | — | CN | disclosed |
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20220288077-A1 | PROSTATITIS TREATMENT | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES (CN) | 2022-09-15 | — | — | US | disclosed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | disclosed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185098-A1 | Inhibitors of protein kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053454-B2 | Compositions for cryopreservation and methods of use thereof | BAK1, BAX, BAD | TEK 4326/4885FLT1 4124/4885RIPK1 12/4885 |
| US-20190201381-A1 | COMPOSITIONS FOR CRYOPRESERVATION AND METHODS OF USE THEREOF | BAX, BAK1, CASP3 | TEK 2662/4885FLT1 3859/4885RIPK1 22/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | TEK 2/4885FLT1 5/4885RIPK1 3433/4885 |
| US-20070185098-A1 | Inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K19 | TEK 1180/4885FLT1 740/4885RIPK1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.